DOI: 10.4244/EIJ-D-20-00676R

Reply: Pitfalls in aerobic capacity estimation of a chronic angina population

Carlo Zivelonghi1, MD; Stefan Verheye1, MD, PhD

We read with interest the letter by Georgios Tzanis et al1 concerning our study “Coronary sinus Reducer implantation results in improved oxygen kinetics at cardiopulmonary exercise test in patients with refractory angina”2.

In brief, in our manuscript we presented, for the first time, data regarding cardiopulmonary exercise testing before and after Reducer implantation. Improvements in oxygen kinetics were shown by increased VO2 max (+11.3%, p=0.026), increased VO2 at anaerobic threshold (+9.1%, p=0.06), and increased effort tolerance of approximately 34% (68±28 W vs 81±49 W, p=0.05). These observations were associated with consistent improvements in Canadian Cardiovascular Society class.

As the authors of the letter stated, our results are in line with previous evidence of reduction in myocardial ischaemia following Reducer implantation3, including an investigation by the same group who described improved parameters of cardiac magnetic resonance imaging. Of key importance, our study design and endpoints – including cardiopulmonary exercise test (CPET) parameters – were similar to a previous investigation by Adachi et al4 reporting comparable results after percutaneous coronary intervention in patients with stable angina (e.g., VO2 max +14%). Furthermore, in the limitations paragraph of our manuscript we also stated that “relative new parameters of oxygen kinetics were not available in our analysis”, such as O2-pulse, O2-pulse flattening duration and ΔVO2/ΔWR slope.

We firmly believe that our results demonstrated for the first time that clinical improvements in patients with refractory angina treated with the Reducer can be translated into a better peak oxygen consumption. This parameter should be considered in studies investigating the possible reduction in myocardial ischaemia after Reducer implantation, unlike the studies cited by Tzanis et al.

While appreciating the dedication and interest of the authors in raising such considerations, we see little scientific value.

Conflict of interest statement

S. Verheye is a consultant for Neovasc Inc. C. Zivelonghi has no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.

Volume 16 Number 16
Mar 19, 2021
Volume 16 Number 16
View full issue


Key metrics

Suggested by Cory

Clinical research

10.4244/EIJ-D-19-00766 Apr 2, 2021
Effects of coronary sinus Reducer implantation on oxygen kinetics in patients with refractory angina
Zivelonghi C et al
free

10.4244/EIJV16I18A265 Apr 2, 2021
Reducing refractory angina
de Silva R and Cheng K
free

10.4244/EIJV9I10A196 Feb 20, 2014
Transcatheter treatment for refractory angina with the coronary sinus Reducer
Konigstein M et al
free

10.4244/EIJ-D-20-00676L Mar 19, 2021
Letter: Pitfalls in aerobic capacity estimation of a chronic angina population
Tzanis G and Giannini F
free

SHORT REPORT

10.4244/EIJ-D-17-00626 Feb 20, 2018
Coronary sinus reducer non-responders: insights and perspectives
Baldetti L et al
free

10.4244/EIJV17I7A94 Sep 20, 2021
Coronary sinus reducer therapy for refractory angina: is it ready for prime time?
Foley M and Al-Lamee R
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved